RecruitingNot ApplicableNCT07374185

Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis

A New Regenerative Medicine Protocol Using Autologous Bone Marrow Mononuclear Cells With Growth Factors to Treat Liver Cirrhosis


Sponsor

Global Stem Cell Center, Baghdad

Enrollment

10 participants

Start Date

Feb 20, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

the study includes patients with liver cirrhosis irrespective of the stage excluding people with active tumor or other major health issue endangering life, the protocol includes the use of autologous bone marrow derived mononuclear cells harvested from the same patient under local anesthesia ,followed by cell concentration and viability testing , then final product is combined with small volume of 2 cc of Wharton gel exosomes 20 billion per to be administered intravenously.


Eligibility

Max Age: 80 Years

Exclusion Criteria3

  • active malignancy.
  • severe sepsis.
  • pregnancy. -

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREAutologous Bone Marrow Aspirate Concentrate

using autologous bone marrow aspirated from iliac crest ,centrifuged and then injected intravenously


Locations(1)

Capital Private Hospital Alrabee Street

Baghdad, Iraq, Iraq

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07374185


Related Trials